title: Mild hyperhomocysteinemia and fibrinolytic factors in patients with history of venous thromboembolism.
abstract: Mild hyperhomocysteinemia is recognized as a risk factor for venous thromboembolism (VTE), though its role in the thrombogenic processes is not understood. Its possible association with impaired fibrinolysis was investigated in 157 patients (61 women, 96 men) below the age of 60 years (43+/-11, mean+/-SD) with a history of objectively confirmed VTE. Patients had significantly higher fasting total plasma homocysteine (tHcy) levels than 138 apparently healthy subjects (8.0, 6.6-9.9 micromol/L vs. 7.2, 5.9-8.6 micromol/L, P=0. 001; median, range between first and third quartile). In 17 of 157 patients (12%) hyperhomocysteinemia (tHcy>11.4 micromol/L for women and tHcy>12.6 micromol/L for men) was established. The adjusted odds ratio as an estimate of relative risk for VTE was 2.3 (0.8-7.0; 95% confidence interval). When patients with hyperhomocysteinemia were compared to patients without hyperhomocysteinemia, no significant differences in t-PA (antigen 9.2+/-5.5 microg/L and 9.7+/-4.7 microg/L, respectively; activity 1.3+/-0.5 IU/mL and 1.3+/-0.7 IU/mL, respectively) and PAI-1 (antigen 19.3+/-17.5 microg/L and 22.6+/-20. 4 microg/L, respectively; activity 15.0+/-12.6 and 15.8+/-13.3 IU/mL, respectively) were observed. In conclusion, this study showed an association between mild hyperhomocysteinemia and VTE, but provided no evidence for an independent association between hyperhomocysteinemia and alterations in fibrinolytic proteins.
authors: Department of Angiology, University Medical Centre, Ljubljana, Slovenia.
authors: M
authors: M
authors: Bozic
authors: M
authors: M
authors: Stegnar
authors: I
authors: I
authors: Fermo
authors: A
authors: A
authors: Ritonja
authors: P
authors: P
authors: Peternel
authors: J
authors: J
authors: Stare
authors: A
authors: A
authors: D'Angelo
mesh_terms: D000328:Adult; D005260:Female; D005343:Fibrinolytic Agents / Q000097:blood*; D006801:Humans; D020138:Hyperhomocysteinemia / Q000097:blood / Q000150:complications* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D012307:Risk Factors; D015842:Serine Proteinase Inhibitors / Q000097:blood; D018709:Statistics, Nonparametric; D013923:Thromboembolism / Q000097:blood / Q000453:epidemiology / Q000209:etiology; D010959:Tissue Plasminogen Activator / Q000097:blood; D020246:Venous Thrombosis / Q000097:blood / Q000453:epidemiology / Q000209:etiology*
chemical_list: D005343:Fibrinolytic Agents; D017395:Plasminogen Activator Inhibitor 1; D015842:Serine Proteinase Inhibitors; D010959:Tissue Plasminogen Activator